Davies C W, Juniper M C, Gray W, Gleeson F V, Chapel H M, Davies R J
Osler Chest Unit, Churchill Hospital, Oxford Radcliffe Trust, Oxford OX3 7LJ, UK.
Thorax. 2000 Jan;55(1):88-90. doi: 10.1136/thorax.55.1.88.
Lymphoid interstitial pneumonitis (LIP) is a rare clinicopathological entity that may be associated with common variable immune deficiency (CVID) and may lead to respiratory failure and death. Some patients may respond to prolonged corticosteroid treatment. We hypothesised that, in view of the predominant T cell nature of LIP, cyclosporin A would be a more appropriate choice of immunosuppressive agent and report the first case of its successful use in a woman with LIP associated with CVID.
淋巴细胞间质性肺炎(LIP)是一种罕见的临床病理实体,可能与常见变异型免疫缺陷(CVID)相关,并可能导致呼吸衰竭和死亡。一些患者可能对长期使用皮质类固醇治疗有反应。我们推测,鉴于LIP主要为T细胞性质,环孢素A可能是更合适的免疫抑制剂选择,并报告首例成功应用于一名患有与CVID相关的LIP女性患者的病例。